Nectin Therapeutics announced dosing of the first solid tumor patient in a Phase I clinical trial Wednesday while additional investors jumped in to expand the company's Series A to just over $25 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,